Westfield Capital Management Co. LP Sells 54,855 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Westfield Capital Management Co. LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 594,437 shares of the company’s stock after selling 54,855 shares during the period. Westfield Capital Management Co. LP owned 0.61% of Neurocrine Biosciences worth $78,323,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of NBIX. First Horizon Advisors Inc. boosted its position in shares of Neurocrine Biosciences by 10.5% in the fourth quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock valued at $103,000 after acquiring an additional 74 shares during the period. Quadrant Capital Group LLC grew its position in shares of Neurocrine Biosciences by 3.9% during the 4th quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock worth $273,000 after purchasing an additional 78 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Neurocrine Biosciences by 3.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after purchasing an additional 78 shares during the period. Sunbelt Securities Inc. raised its position in shares of Neurocrine Biosciences by 34.3% in the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after buying an additional 83 shares in the last quarter. Finally, Balentine LLC boosted its stake in shares of Neurocrine Biosciences by 4.0% in the fourth quarter. Balentine LLC now owns 2,316 shares of the company’s stock valued at $305,000 after buying an additional 89 shares during the period. Institutional investors own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NBIX shares. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Guggenheim boosted their price target on Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Oppenheimer increased their price objective on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Canaccord Genuity Group boosted their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Finally, HC Wainwright upped their price target on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $148.96.

Insider Transactions at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $140.24, for a total value of $2,103,600.00. Following the sale, the chief financial officer now directly owns 31,528 shares in the company, valued at $4,421,486.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Matt Abernethy sold 15,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total value of $2,103,600.00. Following the transaction, the chief financial officer now owns 31,528 shares in the company, valued at $4,421,486.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Shalini Sharp sold 1,106 shares of the stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $141.90, for a total value of $156,941.40. Following the sale, the director now owns 994 shares of the company’s stock, valued at $141,048.60. The disclosure for this sale can be found here. Insiders sold 180,770 shares of company stock worth $25,047,308 over the last ninety days. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX traded down $1.11 during mid-day trading on Friday, reaching $139.40. 423,935 shares of the company’s stock were exchanged, compared to its average volume of 730,788. Neurocrine Biosciences, Inc. has a twelve month low of $89.04 and a twelve month high of $148.37. The firm has a market capitalization of $14.03 billion, a price-to-earnings ratio of 38.40 and a beta of 0.28. The business’s fifty day moving average price is $138.66 and its 200-day moving average price is $131.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The company had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Analysts predict that Neurocrine Biosciences, Inc. will post 4.17 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.